Table 1. Epidemiological characterization of the population with metastatic breast cancer using trastuzumab from 09/2017 to 08/2018 in a reference hospital in oncology in Rio de Janeiro, Brazil.
| Explanatory variables | Staging at diagnosis | |||
|---|---|---|---|---|
| (I–III) n (%) | IV n (%) | Total n (%) | ||
| Age at diagnosis | ||||
| 20–29 | 2 (2.7) | 3 (4.8) | 5 (3.7) | |
| 30–49 | 37 (50.8) | 25 (39.7) | 62 (45.6) | |
| 50–69 | 32 (43.8) | 30 (47.6) | 62 (45.6) | |
| 70–90 | 2 (2.7) | 5 (7.9) | 7 (5.1) | |
| Skin color | ||||
| White | 30 (41.1) | 21 (33.3) | 51 (37.5) | |
| Black and brown | 43 (58.9) | 42 (66.7) | 85 (62.5) | |
| Metastatic site | ||||
| 1_bone | 11 (15.1) | 10 (15.8) | 21 (15.4) | |
| 2_CNS | 7 (9.6) | 2 (3.2) | 9 (6.6) | |
| 3_Liver | 3 (4.1) | 3 (4.8) | 6 (4.4) | |
| 4_Multiple | 34 (46.6) | 36 (57.1) | 70 (51.6) | |
| 5_Lung | 6 (8.2) | 3 (4.8) | 9 (6.6) | |
| 6_Others | 12 (16.4) | 9 (14.3) | 21 (15.4) | |
| Hormone receptor (estrogen or progesterone) | ||||
| Negative | 28 (38.4) | 20 (31.5) | 48 (35.3) | |
| Positive | 45 (61.6) | 43 (68.2) | 88 (64.7) | |
| Prior exposure to trastuzumab | ||||
| Exposed | 41 (56.2) | 7 (11.2) | 48 (35.3) | |
| Not exposed | 32 (43.8) | 56 (88.8) | 88 (64.7) | |
| Types of surgery | ||||
| 1_None | 13 (17.8) | 36 (57.1) | 49 (36.0) | |
| 2_Radical mastectomy | 38 (52.0) | 03 (4.8) | 41 (30.1) | |
| 3_Simple mastectomy | 03 (4.1) | 02 (3.2) | 05 (3.7) | |
| 4_Breast conservative | 07 (9.7) | - | 07 (5.2) | |
| 5_Only secondary tumors | 03 (4.1) | 10 (15.9) | 13 (9.6) | |
| 6_Others only (vascular access support) | 09 (12.3) | 12(19.0) | 21 (15.4) | |
| Histopathological degree | ||||
| G1 | 01 (1.3) | 05 (7.9) | 06 (4.4) | |
| G2 | 38 (52.1) | 36 (57.2) | 74 (54.4) | |
| G3 | 34 (46.6) | 22 (34.9) | 56 (41.2) | |
| Body mass index | ||||
| Normal weight (18.5 to 24.9) | 20 (27.4) | 18 (28.6) | 38 (27.9) | |
| Overweight (25.0 to 29.9) | 31 (42.5) | 25 (39.7) | 56 (41.2) | |
| Obesity (≥30.0) | 22 (30.1) | 20 (31.7) | 42 (30.9) | |